The global Leukapheresis products market is projected to reach USD 98.5 Million by 2027 from USD 65.6 Million in 2022, at a CAGR of 8.5% between 2022 and 2027. The global Leukopaks market is projected to reach USD 784.2 Million by 2027 from USD 146.9 Million in 2022, at a CAGR of 39.8% between 2022 and 2027.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
Market Growth Drivers
- Rising incidence and prevalence of leukemia
- Increasing number of blood donations
- Increased demand for leukopaks in clinical research
Market Growth Opportunities
- Leukapheresis for pediatric patients
- Emerging economies with investments from academic institutes, pharma-biotech companies, and leading players
- Gaps in current leukapheresis technologies
Market Challenges
- Blood transfusion safety in emerging countries
- Industry Trends
- Increasing Number of Collaborations Among Pharma and Biotech Companies
Key Technologies
- Centrifugal-based leukapheresis
- Membrane-based leukapheresis
The prominent players operating in the leukapheresis market are Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US)
“North America to occupy the largest share of the leukapheresis market in 2021
The Leukapheresis market is segmented into four major regions, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World.
North America accounted for the largest share of the Leukapheresis market in 2021. The strong presence of a large number of players and a large number of ongoing CAR T-cell therapy clinical trials are driving the growth of the leukapheresis market in the North American region.
Asia Pacific was the fastest growing region, which can be attributed to the growing number of personalized medicine, regenerative medicine, cell therapy research activities, and increasing funding for CAR T-cell therapy research.
Inquiry Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=20283148
